ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - fluphenazine decanoate - תמיסה להזרקה - fluphenazine decanoate 25 mg/ml - fluphenazine - fluphenazine - management of psychotic disorders.

ישראל - עברית - Ministry of Health

unipharm trading ltd, israel - haloperidol as decanoate - תמיסה להזרקה - haloperidol as decanoate 100 mg/ml - haloperidol - haloperidol - long term maintenance treatment of schizophrenia and mental or behaivoral problems.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 267 mg - pirfenidone

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pirfenidone - טבליה - pirfenidone 801 mg - pirfenidone

ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 5 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia ) or mixed dyslipidaemia ( type iib ) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. hormozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatment are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 10 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 20 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - rosuvastatin as calcium - טבליות מצופות פילם - rosuvastatin as calcium 40 mg - rosuvastatin - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction ) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor